Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis-Reference-Cited by-同舟云学术

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Published:2024-02 Issue:1 Volume:3 Page:100195
ISSN:2772-8293
Container-title:Journal of Allergy and Clinical Immunology: Global
language:en
Short-container-title:Journal of Allergy and Clinical Immunology: Global

Author:

Rewerska Barbara,Sher Lawrence D.,Alpizar Sady,Pauser Sylvia,Pulka Grazyna,Mozaffarian Neelufar,Salhi Yacine,Martinet Camille,Jabert Wafaa,Gudi Girish,CA Vinu,GN Sunitha,Macoin Julie,Anstett Victor,Turrini Riccardo,Doucey Marie-Agnès,Blein Stanislas,Konto Cyril,Machkova Martina

Publisher

Elsevier BV

Reference45 articles.

1. Investigating international time trends in the incidence and prevalence of atopic eczema, 1990-2010: a systematic review of epidemiological studies;Deckers;PLoS One,2012

2. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016

3. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials;Guttman-Yassky;Lancet,2021

4. Assessing the current treatment of atopic dermatitis: unmet needs;Leung;J Allergy Clin Immunol,2017

5. Atopic dermatitis;Stander;N Engl J Med,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Systemic Treatment Options in Atopic Dermatitis;Balkan Medical Journal;2024-07-05

2. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis;British Journal of Dermatology;2024-06-05

3. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond;Expert Opinion on Biological Therapy;2024-06-02

4. The Role of OX40–OX40L Axis in the Pathogenesis of Atopic Dermatitis;Dermatitis®;2024-05-03

5. Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials;Expert Opinion on Emerging Drugs;2024-04-28